Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

Jorge E. Cortes, Dan Jones, Susan O'Brien, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan Kadia, Gautam Borthakur, Denise Stigliano, Jianqin Shan, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant. Patients and Methods: Patients with newly diagnosed CML in chronic phase were treated with nilotinib 400 mg twice daily on an empty stomach as initial therapy. Results: Among 51 patients in chronic phase observed for at least 3 months, 50 (98%) achieved a complete cytogenetic remission (CCyR), and 39 (76%) achieved a major molecular response (MMR). Responses occurred rapidly, with 96% of patients achieving CCyR by 3 months and 98% achieving CCyR by 6 months. The projected event-free survival at 24 months is 90%, and all patients are alive after a median follow-up time of 17 months. Grade ≥ 3 neutropenia occurred in 12% of patients, and thrombocytopenia in occurred 11%. Nonhematologic toxicity was usually grade 1 to 2 and manageable. The actual median dose at 12 months was 800 mg (range, 200 to 800 mg). Conclusion: Nilotinib is an effective option for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR, with most patients reaching these responses early during their therapy.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number3
DOIs
StatePublished - Jan 20 2010
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Leukemia, Myeloid, Chronic Phase
Therapeutics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Neutropenia
Thrombocytopenia
Disease-Free Survival
Stomach

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. / Cortes, Jorge E.; Jones, Dan; O'Brien, Susan; Jabbour, Elias; Konopleva, Marina; Ferrajoli, Alessandra; Kadia, Tapan; Borthakur, Gautam; Stigliano, Denise; Shan, Jianqin; Kantarjian, Hagop.

In: Journal of Clinical Oncology, Vol. 28, No. 3, 20.01.2010, p. 392-397.

Research output: Contribution to journalArticle

Cortes, JE, Jones, D, O'Brien, S, Jabbour, E, Konopleva, M, Ferrajoli, A, Kadia, T, Borthakur, G, Stigliano, D, Shan, J & Kantarjian, H 2010, 'Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase', Journal of Clinical Oncology, vol. 28, no. 3, pp. 392-397. https://doi.org/10.1200/JCO.2009.25.4896
Cortes, Jorge E. ; Jones, Dan ; O'Brien, Susan ; Jabbour, Elias ; Konopleva, Marina ; Ferrajoli, Alessandra ; Kadia, Tapan ; Borthakur, Gautam ; Stigliano, Denise ; Shan, Jianqin ; Kantarjian, Hagop. / Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 3. pp. 392-397.
@article{e5f8c124a1f84881bdef735452a83e81,
title = "Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase",
abstract = "Purpose: Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant. Patients and Methods: Patients with newly diagnosed CML in chronic phase were treated with nilotinib 400 mg twice daily on an empty stomach as initial therapy. Results: Among 51 patients in chronic phase observed for at least 3 months, 50 (98{\%}) achieved a complete cytogenetic remission (CCyR), and 39 (76{\%}) achieved a major molecular response (MMR). Responses occurred rapidly, with 96{\%} of patients achieving CCyR by 3 months and 98{\%} achieving CCyR by 6 months. The projected event-free survival at 24 months is 90{\%}, and all patients are alive after a median follow-up time of 17 months. Grade ≥ 3 neutropenia occurred in 12{\%} of patients, and thrombocytopenia in occurred 11{\%}. Nonhematologic toxicity was usually grade 1 to 2 and manageable. The actual median dose at 12 months was 800 mg (range, 200 to 800 mg). Conclusion: Nilotinib is an effective option for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR, with most patients reaching these responses early during their therapy.",
author = "Cortes, {Jorge E.} and Dan Jones and Susan O'Brien and Elias Jabbour and Marina Konopleva and Alessandra Ferrajoli and Tapan Kadia and Gautam Borthakur and Denise Stigliano and Jianqin Shan and Hagop Kantarjian",
year = "2010",
month = "1",
day = "20",
doi = "10.1200/JCO.2009.25.4896",
language = "English (US)",
volume = "28",
pages = "392--397",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

AU - Cortes, Jorge E.

AU - Jones, Dan

AU - O'Brien, Susan

AU - Jabbour, Elias

AU - Konopleva, Marina

AU - Ferrajoli, Alessandra

AU - Kadia, Tapan

AU - Borthakur, Gautam

AU - Stigliano, Denise

AU - Shan, Jianqin

AU - Kantarjian, Hagop

PY - 2010/1/20

Y1 - 2010/1/20

N2 - Purpose: Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant. Patients and Methods: Patients with newly diagnosed CML in chronic phase were treated with nilotinib 400 mg twice daily on an empty stomach as initial therapy. Results: Among 51 patients in chronic phase observed for at least 3 months, 50 (98%) achieved a complete cytogenetic remission (CCyR), and 39 (76%) achieved a major molecular response (MMR). Responses occurred rapidly, with 96% of patients achieving CCyR by 3 months and 98% achieving CCyR by 6 months. The projected event-free survival at 24 months is 90%, and all patients are alive after a median follow-up time of 17 months. Grade ≥ 3 neutropenia occurred in 12% of patients, and thrombocytopenia in occurred 11%. Nonhematologic toxicity was usually grade 1 to 2 and manageable. The actual median dose at 12 months was 800 mg (range, 200 to 800 mg). Conclusion: Nilotinib is an effective option for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR, with most patients reaching these responses early during their therapy.

AB - Purpose: Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant. Patients and Methods: Patients with newly diagnosed CML in chronic phase were treated with nilotinib 400 mg twice daily on an empty stomach as initial therapy. Results: Among 51 patients in chronic phase observed for at least 3 months, 50 (98%) achieved a complete cytogenetic remission (CCyR), and 39 (76%) achieved a major molecular response (MMR). Responses occurred rapidly, with 96% of patients achieving CCyR by 3 months and 98% achieving CCyR by 6 months. The projected event-free survival at 24 months is 90%, and all patients are alive after a median follow-up time of 17 months. Grade ≥ 3 neutropenia occurred in 12% of patients, and thrombocytopenia in occurred 11%. Nonhematologic toxicity was usually grade 1 to 2 and manageable. The actual median dose at 12 months was 800 mg (range, 200 to 800 mg). Conclusion: Nilotinib is an effective option for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR, with most patients reaching these responses early during their therapy.

UR - http://www.scopus.com/inward/record.url?scp=75749090051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749090051&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.25.4896

DO - 10.1200/JCO.2009.25.4896

M3 - Article

C2 - 20008621

AN - SCOPUS:75749090051

VL - 28

SP - 392

EP - 397

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -